Paragon partners with like-minded innovative organizations that are at the pinnacle of their respective fields. Every partnership is different, but all are grounded in exceptional quality, scientific
expertise and an exceptional product.
CAP®GT cells propagate a broad spectrum of viral species supporting lentiviral (LV), adenoviral (AV) and adeno-associated viral (AAV) vectors. Paragon and CEVEC have co-developed a scalable clinical production process for AAV gene therapy vectors based on the CAP®GT expression system.
CAP®GO cells have been used to produce glycol-optimized proteins ranging from virus envelope proteins to cytokines and antibodies. In partnership with CEVEC, Paragon increased traditionally low titer recombinant proteins to exhibit authentic glycosylation and enhanced product quality.
More information: www.CEVEC.com
Follow CEVEC on LinkedIn.
Cevec Pharmaceuticals GmbH
Paragon is CEVEC’s preferred CDMO in North America. Together, both organizations co-market CEVEC’s proprietary CAP® as well as Paragon’s experiences and proficiency regarding CAP®-based research and development in conjunction with GMP manufacturing for Phase I/II clinical trials.
Operational since 2004 and located in Cologne, Germany, CEVEC specializes in developing and producing tailor-made recombinant glycoproteins, gene therapy vectors, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC’s proprietary CAP® Technology is the new industry standard for scalable mammalian production in North America.